Author: Prohost

Alnylam Pharmaceuticals Receives EC Approval for AMVUTTRA® for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceutical's News Today is Great Before we get to the press release from Alnylam Pharmaceuticals we remind that tomorrow, Tuesday, June 10, 2025,  Akero Therapeutics’ management will present at Goldman Sachs 46th Annual Global Healthcare Conference at 2:40 pm Et. The presentation will be available through the investor relations section of the company’s website at www.akerotx.com. An archived replay will be available for those …

Why Prohost Decided To Pick Soleno Therapeutics For Investment

Soleno Therapeutics Soleno Therapeutics (SLNO) announced that’s Marketing Authorization Application (MAA) seeking regulatory approval of Diazoxide Choline Prolonged-Release Tablets for the treatment of adults and children four years and older with Prader-Willi syndrome (PWS) who have hyperphagia had been validated by the European Medicines Agency (EMA). From Soleno Therapeutics “The validation . . . This content is for paid subscribers. Please click here to subscribe or …

Important News For Vera Therapeutics

Vera Therapeutics As expected, Vera Therapeutics (VERA) product Ataticept achieved proteinuria reduction in ORIGIN Phase 3 trials in adults with IgA nephropathy. This is indeed great news! The trial met the primary endpoint at week 36. Ataticept has achieved 46%reduction from baseline and 42%reduction compared to placebo on wek 36. Vera is not sharing cGFR at this time . . . This content is for …

Why Many Biotech Investors Believe Akero Therapeutics Will Soon Be Acquired By A Top-Tier Company

Akero Therapeutics Akero Therapeutics (AKRO) - a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Currently, many investors, including us, believe that . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Answering Questions About Vera Therapeutics

Vera Therapeutics Q: What did Vera Therapeutics announce on May 6th that is more than what we knew before?  A: On May 6th Vera Therapeutics (VERA) provided business  Update and Reported  First Quarter 2025 Financial Results on  track to announce the primary endpoint results from the atacicept pivotal . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Exelixis First Quarter 2025 Financial Results Plus Corporate Update

Exelixis in the NEWS   Two days ago, Exelixis (EXEL) reported financial results for the first quarter of 2025, providing an update on the firm’s progress toward achieving key corporate objectives, and outlined its commercial, clinical, and pipeline development milestones. From Exelixis Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis said, " Exelixis has delivered outstanding financial performance . . . This content is …

Will A Great Yesterday Erase The World’s Stress After U.S And China’s Agreement Over Tariffs? Also Read About The Resurrected CytomX Therapeutics 

Yesterday's Market and CytomX Therapeutics May 12, 2025 was an excellent day for many stressed countries. The good day began following the U.S. and China’s announcement of an agreement on Tariffs Many countries have been stressed since being attacked by COVID-19 and then the war in Europe and the Middle East as well as unparallelled inflations.   Yesterday, the Stock market rallied and with it …

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

PTC Therapeutics On May 6, 2025, PTC Therapeutics (PTCT) announced a corporate update and financial results for the first quarter ended March 31, 2025. We loved the firm’s strong revenue performance of $190 million,  the positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, and, important is the  NDA review remained on track for July 29, 2025, PDUFA date, the . . . This …

Alnylam Pharmaceuticals Reported Its Q1 2025 Financial Results and Highlights Recent Period Progress

Alnylam Pharmaceuticals Synopsis  Today, May 1, 2025 - Alnylam Pharmaceuticals (ALNY), the leading RNAi therapeutics company reported its consolidated financial results for the first quarter ended March 31, 2025 and reviewed recent business highlights. From Alnylam Pharmaceuticals Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam Pharmaceuticals, said, “2025 is off to a remarkable start, having ended the first quarter with U.S . . . This …

Important Biotechnology Companies’ News, Plus News from the American Association for Cancer Research and More 

Important News from AbbVie AbbVie (ABBV) submitted a biological license application (BLA) to the United States’ FDA for its sensational product trenibotulinumtoxinE (TrenibotE), which reduces frown lines between the eyebrows, known as glabellar lines. The Product TrenibotE is a botulinum toxin of serotype E with short effects of a long duration for the users. The product is safer than the existing . . . This …

Vera Therapeutics ORIGIN Phase 3 Trial for Atacicept in IgAN

We still believe in many outperforming biotechnology firms whose stocks are underestimated on Wall Street. We believe these firms are outperforming in science but not yet in the Stock Market. We will continue to post them on our website. One of the firms that we recently liked after assessment is Vera Therapeutics.   Vera Therapeutics Vera Therapeutics (

Why and How the Stock Market Rallied Plus a Combination That Treated a Severe Colorectal Cancer

Today's Stock Market Rally Today, Wednesday, April 9, 2025 the news started with Trump announcing a '90-day pause' on tariffs for most countries. What happened next was a rallying Stock Market with the Dow, the S&P 500 and the Nasdaq soaring.   The S&P 500 climbed up around 8%, the Nasdaq Composite rallied 10% and the Dow Jones Industrial Average was up over 7%. President …

Why Rhythm Pharmaceuticals Stock Rallied While The Market Was Tumbling

Rhythm Pharmaceuticals Rally Last week, almost all the stocks tumbled. On Monday, the first day of the current week, we could see biotech firms usually moving up after good news, which didn’t occur during the few bad days of the market's tumbling.  One of the health firm’s sectors Rhythm Pharmaceuticals (RYTM) rallied after having more promising news . . . This content is for paid subscribers. …

Novo Nordisk at ACC 2025: Ozempic® with Once Weekly Semaglutide 1mg Shown to Improve Walking Distance and Quality of Life in Adults with Type 2 Diabetes and Peripheral Artery Disease

Novo Nordisk in the NEWS Novo Nordisk (NVO) presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) in adults with type 2 diabetes and PAD, at the American College of Cardiology's (ACC) Annual Scientific Session and Expo in Chicago, US . . . This content is for paid subscribers. …

The U.S. FDA Approved Alnylam Pharmaceuticals’ Product Qfitlia to Treat Hemophilia A or B With or Without Inhibitors

Stock Market Plummet and Alnylam Pharmaceuticals Good News Today, the stock market is plummeting. In fact, most stocks have been falling since early morning. The reason has nothing to do with the company’s activities. The best companies with the best science and scientists are sinking into the bottom of the deepest ocean today. Even though the Stock Market is surrounded by negativity, we will still …

Wave Life Sciences Announced What Could be Excellent News in Treating Duchenne Muscular Dystrophy

Wave Life Sciences On March 26, 2025, Wave Life Sciences (WVE) announced positive data from the Phase 2 FORWARD-53 trial of WVE-N531, an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. FORWARD-53 Trial demonstrates sustained and industry-leading exon . . . This content is for paid subscribers. Please click here to subscribe or here to log …

BridgeBio Pharma to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-Type Transthyretin Amyloid Cardiomyopathy at the ACC Annual Scientific Sessions

BridgeBio Pharma Today, March 24, 2025, BridgeBio Pharma, Inc. (BBIO) announced that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Results from PTC Therapeutics’ Latest Presentation

PTC Therapeutics Inc On March 20, 2025, PTC Therapeutics, Inc. (PTCT) shared new data from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. These data provide further evidence of the potential meaningful benefits of sepiapterin treatment for the full spectrum of phenylketonuria (PKU . . . This content is for paid …

FDA Approved Alnylam Pharmaceuticals sNDA for AMVUTTRA® – A Treatment for Cardiomyopathy of Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis in Adults to Reduce Cardiovascular Mortality, Cardiovascular Hospitalizations and Urgent Heart Failure Visits

Alnylam Pharmaceuticals in the NEWS March 20, 2025, Alnylam Pharmaceuticals (ALNY) - the leading RNAi therapeutics company, today announced that the U.S. FDA has approved the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA® (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to . . . This content is for paid subscribers. Please click here to subscribe or …